J Korean Med Sci.  2021 Aug;36(34):e219. 10.3346/jkms.2021.36.e219.

Efficacy of Triptorelin 3-Month Depot Compared to 1-Month Depot for the Treatment of Korean Girls with Central Precocious Puberty in Single Tertiary Center

Affiliations
  • 1Department of Pediatrics, Myongji Hospital, Hanyang University College of Medicine, Goyang, Korea
  • 2Department of Pediatrics, Korea University College of Medicine, Seoul, Korea

Abstract

Background
Triptorelin depot is largely used to treat central precocious puberty (CPP) in children, and a 3-month depot has been introduced. However, data about the 3-month gonadotropin-releasing hormone use for treatment of CPP in Korean girls are not available. This study was conducted to compare the efficacy of a triptorelin 11.25 mg 3-month depot with that of a 3.75 mg 1-month depot in suppressing pubertal development for the treatment of CPP.
Methods
A retrospective study, including 106 girls with CPP treated with triptorelin, was conducted. Fifty patients were treated with a triptorelin 3-month depot, and 56 were treated with a triptorelin 1-month depot. Serum luteinizing hormone (LH), follicle-stimulating hormone, and estradiol levels were analysed every 6 months after the visit. The height and bone age of each patient was evaluated at the beginning of treatment, after 6 months, and one year after therapy.
Results
The baseline characteristics of the girls treated with a 3-month depot were similar to those of the girls treated with a 1-month depot. A suppressed levels of LH to the triptorelin injection (serum LH < 2.5 IU/L) at 6 months was seen in 90.0% and 98.2% of the girls treated with the 3-month and 1-month depots, respectively (P = 0.160). After 1 year of treatment, a suppressed levels of LH was seen in 93.5% and 100% of the girls treated with the 3-month and 1-month depots, respectively (P = 0.226). Height velocity showed no significant difference between the two groups. Degree of bone age advancement decreased from 1.22 ± 0.07 and 1.22 ± 0.08 years at baseline (P = 0.914) to 1.16 ± 0.07 and 1.17 ± 0.08 in the girls treated with the 3-month and 1-month depots after 1 year, respectively (P = 0.481).
Conclusion
This study showed that the efficacy of long-acting triptorelin 3-month was comparable to 1-month depot regarding hormonal suppression and inhibition of bone maturation. The triptorelin 11.25 mg 3-month depot is an effective treatment for girls with CPP.

Keyword

Central Precocious Puberty; Triptorelin Pamoate; Gonadotropin-releasing; Hormone Analogue; Korea

Figure

  • Fig. 1 Flow chart of the study population.TP = triptorelin pamoate, TA = triptorelin acetate, ADR = adverse drug reaction, CPP = central precocious puberty.


Reference

1. Nebesio TD, Eugster EA. Current concepts in normal and abnormal puberty. Curr Probl Pediatr Adolesc Health Care. 2007; 37(2):50–72. PMID: 17223057.
Article
2. Nathan BM, Palmert MR. Regulation and disorders of pubertal timing. Endocrinol Metab Clin North Am. 2005; 34(3):617–641. PMID: 16085163.
Article
3. Carel JC, Eugster EA, Rogol A, Ghizzoni L, Palmert MR, Antoniazzi F, et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics. 2009; 123(4):e752–e762. PMID: 19332438.
Article
4. Carel JC, Eugster EA, Rogol A, Ghizzoni L, Palmert MR, Antoniazzi F, et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics. 2009; 123(4):e752–e762. PMID: 19332438.
Article
5. Kim YJ, Lee HS, Lee YJ, Lim JS, Kim SY, Kim EY, et al. Multicenter clinical trial of leuprolide acetate depot (Luphere depot 3.75 mg) for efficacy and safety in girls with central precocious puberty. Ann Pediatr Endocrinol Metab. 2013; 18(4):173–178. PMID: 24904873.
Article
6. Müller J, Juul A, Andersson AM, Sehested A, Skakkebaek NE. Hormonal changes during GnRH analogue therapy in children with central precocious puberty. J Pediatr Endocrinol Metab. 2000; 13(Suppl 1):739–746. PMID: 10969916.
Article
7. Baek JW, Nam HK, Jin D, Oh YJ, Rhie YJ, Lee KH. Age of menarche and near adult height after long-term gonadotropin-releasing hormone agonist treatment in girls with central precocious puberty. Ann Pediatr Endocrinol Metab. 2014; 19(1):27–31. PMID: 24926460.
Article
8. Padula AM, Macmillan KL. Oestradiol-17beta responsiveness, plasma LH profiles, pituitary LH and FSH concentrations in long-term ovariectomised Holstein cows at 24 h, 48 h and 21 days following treatment with an absorbable GnRH agonist implant. Anim Reprod Sci. 2005; 85(1-2):27–39. PMID: 15556306.
9. Lahlou N, Carel JC, Chaussain JL, Roger M. Pharmacokinetics and pharmacodynamics of GnRH agonists: clinical implications in pediatrics. J Pediatr Endocrinol Metab. 2000; 13(Suppl 1):723–737. PMID: 10969915.
Article
10. Chiocca E, Dati E, Baroncelli GI, Cassio A, Wasniewska M, Galluzzi F, et al. Central precocious puberty: treatment with triptorelin 11.25 mg. Sci World J. 2012; 2012:583751.
11. Carel JC, Blumberg J, Seymour C, Adamsbaum C, Lahlou N. Triptorelin 3-month CPP Study Group. Three-month sustained-release triptorelin (11.25 mg) in the treatment of central precocious puberty. Eur J Endocrinol. 2006; 154(1):119–124. PMID: 16382000.
Article
12. Martínez-Aguayo A, Hernández MI, Beas F, Iñiguez G, Avila A, Sovino H, et al. Treatment of central precocious puberty with triptorelin 11.25 mg depot formulation. J Pediatr Endocrinol Metab. 2006; 19(8):963–970. PMID: 16995580.
Article
13. Badaru A, Wilson DM, Bachrach LK, Fechner P, Gandrud LM, Durham E, et al. Sequential comparisons of one-month and three-month depot leuprolide regimens in central precocious puberty. J Clin Endocrinol Metab. 2006; 91(5):1862–1867. PMID: 16449344.
Article
14. Fuld K, Chi C, Neely EK. A randomized trial of 1- and 3-month depot leuprolide doses in the treatment of central precocious puberty. J Pediatr. 2011; 159(6):982–987.e1. PMID: 21798557.
Article
15. Neely EK, Wilson DM, Lee PA, Stene M, Hintz RL. Spontaneous serum gonadotropin concentrations in the evaluation of precocious puberty. J Pediatr. 1995; 127(1):47–52. PMID: 7608810.
Article
16. Ab Rahim SN, Omar J, Tuan Ismail TS. Gonadotropin-releasing hormone stimulation test and diagnostic cutoff in precocious puberty: a mini review. Ann Pediatr Endocrinol Metab. 2020; 25(3):152–155. PMID: 32871650.
Article
17. Greulich WW, Pyle SI. Radiographic atlas of skeletal development of the hand and wrist: based on the brush foundation study of human growth and development initiated by T. Wingate Todd, M.B., Ch. B., F.R.C.S. JAMA. 1950; 143(12):1124.
18. Kim YM, Choi JH, Lee BH, Yoo HW. Efficacy of a single luteinizing hormone measurement after GnRH agonist administration for therapeutic monitoring of girls with central precocious puberty. Ann Pediatr Endocrinol Metab. 2012; 17(3):153–159.
Article
19. Kim JH, Yun S, Hwang SS, Shim JO, Chae HW, Lee YJ, et al. The 2017 Korean national growth charts for children and adolescents: development, improvement, and prospects. Korean J Pediatr. 2018; 61(5):135–149. PMID: 29853938.
Article
20. Tanner JM. Growth at Adolescence. Oxford, London: Blackwell;1962.
21. Bertelloni S, Arrigo T, Wasniewska M, Galluzzi F, Einaudi S, Cappa M, et al. Central precocious puberty: short-term comparative data of treatment with monthly or long-acting three months depot triptorelin. J Pediatr Endocrinol Metab. 2007; 20:297–305.
22. Bertelloni S, Massart F, Einaudi S, Wasniewska M, Miccoli M, Baroncelli GI. Central precocious puberty: adult height in girls treated with quarterly or monthly gonadotropin-releasing hormone analog triptorelin. Horm Res Paediatr. 2015; 84(6):396–400. PMID: 26528763.
Article
23. Heo S, Lee YS, Yu J. Basal serum luteinizing hormone value as the screening biomarker in female central precocious puberty. Ann Pediatr Endocrinol Metab. 2019; 24(3):164–171. PMID: 31607109.
Article
24. Houk CP, Kunselman AR, Lee PA. The diagnostic value of a brief GnRH analogue stimulation test in girls with central precocious puberty: a single 30-minute post-stimulation LH sample is adequate. J Pediatr Endocrinol Metab. 2008; 21(12):1113–1118. PMID: 19189683.
Article
25. Lee PA, Luce M, Bacher P. Monitoring treatment of central precocious puberty using basal luteinizing hormone levels and practical considerations for dosing with a 3-month leuprolide acetate formulation. J Pediatr Endocrinol Metab. 2016; 29(11):1249–1257. PMID: 27740929.
Article
26. Demirbilek H, Alikasifoglu A, Gonc NE, Ozon A, Kandemir N. Assessment of gonadotrophin suppression in girls treated with GnRH analogue for central precocious puberty; validity of single luteinizing hormone measurement after leuprolide acetate injection. Clin Endocrinol (Oxf). 2012; 76(1):126–130. PMID: 21790701.
Article
27. Brito VN, Latronico AC, Arnhold IJ, Mendonca BB. A single luteinizing hormone determination 2 hours after depot leuprolide is useful for therapy monitoring of gonadotropin-dependent precocious puberty in girls. J Clin Endocrinol Metab. 2004; 89(9):4338–4342. PMID: 15356030.
Article
28. Lucaccioni L, McNeilly J, Mason A, Giacomozzi C, Kyriakou A, Shaikh MG, et al. The measurement of urinary gonadotropins for assessment and management of pubertal disorder. Hormones (Athens). 2016; 15(3):377–384. PMID: 27838606.
Article
29. Poomthavorn P, Khlairit P, Mahachoklertwattana P. Subcutaneous gonadotropin-releasing hormone agonist (triptorelin) test for diagnosing precocious puberty. Horm Res. 2009; 72(2):114–119. PMID: 19690429.
Article
30. Lee PA. Laboratory monitoring of children with precocious puberty. Arch Pediatr Adolesc Med. 1994; 148(4):369–376. PMID: 8148936.
Article
31. Eckert KL, Wilson DM, Bachrach LK, Anhalt H, Habiby RL, Olney RC, et al. A single-sample, subcutaneous gonadotropin-releasing hormone test for central precocious puberty. Pediatrics. 1996; 97(4):517–519. PMID: 8632938.
Article
32. Neely EK, Hintz RL, Wilson DM, Lee PA, Gautier T, Argente J, et al. Normal ranges for immunochemiluminometric gonadotropin assays. J Pediatr. 1995; 127(1):40–46. PMID: 7608809.
Article
33. Martínez-Aguayo A, Hernández MI, Beas F, Iñiguez G, Avila A, Sovino H, et al. Treatment of central precocious puberty with triptorelin 11.25 mg depot formulation. J Pediatr Endocrinol Metab. 2006; 19(8):963–970. PMID: 16995580.
Article
34. Zenaty D, Blumberg J, Liyanage N, Jacqz-Aigrain E, Lahlou N, Carel JC. A 6-month trial of the efficacy and safety of triptorelin pamoate (11.25 mg) every 3 months in children with precocious puberty: a retrospective comparison with triptorelin acetate. Horm Res Paediatr. 2016; 86(3):188–195. PMID: 27603324.
Article
Full Text Links
  • JKMS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr